問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taichung Veterans General Hospital

List

1449Cases

2023-05-01 - 2026-05-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-04-30 - 2026-10-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-04-01 - 2026-12-31

Phase I

Active
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic Anti-CD20 Antibody-Conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies

  • Condition/Disease

    B-cell Lymphoma

  • Test Drug

    靜脈點滴注射劑

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2024-12-01 - 2027-12-31

Phase I

Active
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T cell (gdT) Therapy in Adult Subjects with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

  • Condition/Disease

    Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

  • Test Drug

    injective

Participate Sites
5Sites

Recruiting5Sites

2015-05-01 - 2018-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-01-01 - 2017-12-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2016-08-01 - 2019-07-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2017-07-01 - 2018-12-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-08-01 - 2016-07-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2025-09-01 - 2031-06-30

Phase III

Not yet recruiting
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2 or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

  • Condition/Disease

    BRCA1, BRCA2 or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

  • Test Drug

    injective tablet

Participate Sites
6Sites

Recruiting6Sites

1 47 48 49 50 51 145
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB